Home | Welcome to Contract Pharma   
Last Updated Friday, October 24 2014
Print

BASi, NanoViricides in Tox-Pact



Published November 13, 2012
Related Searches: Toxicology Clinical Trials Development
NanoViricides has entered into an agreement with BASi to conduct drug development studies for IND applications to the FDA for its nanoviricides drug candidates against various viral diseases.
 
BASi will conduct cGLP and non-GLP studies that are designed to assess overall safety in animals receiving multiple doses of FluCide. Specific safety pharmacology studies will also be conducted to assess the effects of FluCide on cardiovascular, respiratory and central nervous systems. These studies are required for IND submission, as well as applications for clinical trials in other countries such as Australia.
 
NanoViricides anticipates that it will need very large quantities of the drug candidate for these toxicology package studies and is currently performing scale-up studies to produce the necessary quantities. Financial terms of the pact were not disclosed.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On